Table 7. Univariate Analysis of Survival – Extrahepatic CCA.

RISK FACTOR	MEDIAN PFS (Months)	p-value	95% CI	MEDIAN OS (Months)	p-value	95% CI
Clinical Stage
Stage II	NA		10.5 – NA	NA	0.02864	NA – NA
Stage III	8.6		3.3 – NA	19.9		16.1 – NA
Stage IV	6.1	0.2516	5.7–10.1	10.4		9.9 - NA
Surgery
No	5.9	0.0055	3.1 – NA	10.4	0.0064	9.9 – NA
Yes	40.0		8.8 - NA	42.5		16.1 - NA
Radiation
No	6.1	0.0496	3.3 – NA	15.4	0.006144	10.4 – NA
Yes	40.0		8.6 - NA	42.5		NA - NA
Gender
Female	6.0	0.9625	3.3 – NA	16.1	0.5226	10.4 – NA
Male	8.8		6.1 - NA	19.9		15.4 - NA
Ethnicity
Asian	6.1	0.4504	NA – NA	NA	0.5673	NA – NA
White	8.8		6.0 – NA	16.1		11.8 – NA
TP53
No	6.1	0.8454	3.3 – NA	16.1	0.7181	10.4 – NA
Yes	8.8		6.7 – NA	19.9		15.4 – NA
KRAS
No	5.9	0.1864	3.1 – NA	11.8	0.213	10.4 – NA
Yes	10.5		8.8 – NA	19.9		15.4 - NA
ARID1A
No	8.6	0.2948	6.0 – NA	16.1	0.5134	11.8 – NA
Yes	NA		NA – NA	NA		NA – NA
ERBB2
No	8.6	0.7539	6.0 – NA	42.5	0.1248	15.4 – NA
Yes	8.8		3.1 – NA	11.8		8.9 – NA
PBRM1
No	8.8	0.07583	6.1 – NA	19.9	0.004671	15.4 – NA
Yes	3.1		NA – NA	8.9		NA – NA
BAP1
No	8.8	0.002	4.1–13.4	19.9	0.007	6.1–33.7
Yes	3.0		NA – NA	8.9		NA – NA
FBXW7
No	6.7		5.3 – NA	16.1		10.4 – NA
Yes	NA		8.6 – NA	NA		NA – NA
SMAD4
No	6.1		3.3 –NA	19.9		11.8 – NA
Yes	NA		6.7 – NA	NA		15.4 – NA
MAP/ERK Pathway
No	3.3	0.6695	3.3 – NA	16.1	0.5933	10.4 – NA
Yes	8.8		6.7 – NA	19.9		15.4 – NA
mTOR Pathway
No	6.7	0.3786	3.3–19.4	16.1	0.3686	11.8 – NA
Yes	24.3		6.0 – NA	42.5		10.4 – NA
DNA Repair Pathway
No	8.6	0.5778	6.0 – NA	16.1	0.5135	11.8 – NA
Yes	8.7		3.1 – NA	19.9		8.9 – NA
FGF Pathway
No	8.8	0.000013	6.1 – NA	19.9	0.3038	15.4 – NA
Yes	2.5		NA – NA	11.8		NA – NA
Chromatin modification Pathway
No	8.8	0.5118	6.1 – NA	19.9	0.1392	15.4 – NA
Yes	3.1		3.0 – NA	10.4		8.9 – NA